Mika

The company's core offering is the Mika app, a digital therapeutic (DTx) platform designed to support cancer patients through their treatment journey. The app functions as a digital companion, providing personalized guidance to help patients manage the psychological and physical challenges of cancer. Key features include tools for tracking symptoms and side effects, medication and appointment reminders, and a library of expert-verified articles on treatment options and nutrition. The platform also offers programs for mental health support, such as guided mindfulness journeys and relaxation exercises, aimed at reducing anxiety, depression, and fatigue. This content is developed in partnership with leading oncological research institutions, including Berlin's Charité Hospital and Leipzig University Hospital.

Mika's business model has evolved. Initially, the company aimed for reimbursement through Germany's Digital Health Application (DiGA) framework, which allows doctors to prescribe certified medical apps to patients covered by public health insurance. Mika became the first DiGA approved for all types of cancer in 2021. However, the company later withdrew from the DiGA directory, with the founder citing roadblocks with insurers, and shifted its strategy to B2B partnerships. The app is now offered for free to patients and caregivers in the United States through a partnership with the Cancer Support Community. The company also collaborates with pharmaceutical firms. In June 2025, Boston-based Outcomes4Me announced the acquisition of the Mika Health app's assets from Fosanis GmbH, aiming to combine Mika's emotional support technology and European presence with its own platform to create a more comprehensive digital companion for cancer patients globally.